Letrozole ovulation regimen for frozen-thawed embryo transfer in women with polycystic ovary syndrome: a muti-centre randomised controlled trial

作者：Yanqiu Xie, Ping Li, Guimin Hao, Weifen Deng, Junli Zhao, Shanshan Gao, Bingbing Deng, Yanping Li, Min Deng, Yingying Yuan, Qi Fan, Ningzhen Zhang, Zhiming Zhao, Yuhua Shi · 发表于：Reproductive Biology and Endocrinology · 年份：2025 · DOI：10.1186/s12958-025-01432-w · 被引用次数：5 · 研究领域：Ovarian function and disorders、Reproductive Biology and Fertility、Gynecological conditions and treatments

BACKGROUND: Polycystic ovary syndrome (PCOS) patients typically undergo either an ovulation induction regimen or a programmed regimen for endometrial preparation before frozen embryo transfer (FET). However, the superiority of one approach over the other remains controversial. While previous studies suggest that the letrozole regimen may improve pregnancy outcomes, prospective studies are insufficient. Therefore, we designed a multi-center randomized controlled trial to compare the pregnancy outcomes between these two regimens in PCOS patients undergoing FET. METHODS: This multicentre, randomised controlled, open-label trial included 155 PCOS patients from six hospitals in China between September 2022 and February 2024. Patients were randomised into either the letrozole ovulation regimen group (n = 81) or the programmed regimen group (n = 74) during FET cycles. Subgroup analysis was used among patients with single blastocyst transfer. The primary outcome was clinical pregnancy rate, with secondary outcomes including abortion rate, live birth rate, and other pregnancy and neonatal outcomes. RESULTS: Analysis of 155 FET women showed no significant difference in clinical pregnancy rates between the letrozole group (62.96%) and the programmed group (60.81%, P > 0.05). Similarly, no differences were observed in abortion rate, live birth rate, hypertensive disorders of pregnancy, gestational diabetes mellitus, preterm birth, or neonatal birth weight. However, more patients in the l...